Abstract
Various natural products, such as physostigmine, have long been recognized as inhibitors of the enzyme acetylcholinesterase. Since the recent approval of galanthamine for the treatment of Alzheimers disease by the blockage of acetylcholine degradation, attempts to find other inhibitors of the enzyme have multiplied, leading to promising candidates such as huperzine A. In this review, a listing is presented of natural product inhibitors, both alkaloid and nonalkaloid in origin. These have been isolated from plant, animal and microbial sources. Details of current testing methods on cholinesterases are given, including solution assays and screening techniques by TLC and HPLC.
Keywords: TLC Assays, HPLC Assay, Radiometric Method, AChE activity, Physostigmine, Huperzine A, Amaryllidaceae, Xanthone inhibitors
Current Organic Chemistry
Title: Natural Product Inhibitors of Acetylcholinesterase
Volume: 10 Issue: 8
Author(s): K. Hostettmann, A. Borloz, A. Urbain and A. Marston
Affiliation:
Keywords: TLC Assays, HPLC Assay, Radiometric Method, AChE activity, Physostigmine, Huperzine A, Amaryllidaceae, Xanthone inhibitors
Abstract: Various natural products, such as physostigmine, have long been recognized as inhibitors of the enzyme acetylcholinesterase. Since the recent approval of galanthamine for the treatment of Alzheimers disease by the blockage of acetylcholine degradation, attempts to find other inhibitors of the enzyme have multiplied, leading to promising candidates such as huperzine A. In this review, a listing is presented of natural product inhibitors, both alkaloid and nonalkaloid in origin. These have been isolated from plant, animal and microbial sources. Details of current testing methods on cholinesterases are given, including solution assays and screening techniques by TLC and HPLC.
Export Options
About this article
Cite this article as:
Hostettmann K., Borloz A., Urbain A. and Marston A., Natural Product Inhibitors of Acetylcholinesterase, Current Organic Chemistry 2006; 10 (8) . https://dx.doi.org/10.2174/138527206776894410
DOI https://dx.doi.org/10.2174/138527206776894410 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotective Effects of Nonsteroidal Anti-inflammatory Drugs on Neurodegenerative Diseases
Current Pharmaceutical Design Leptin and the Ob-Receptor as Anti-Obesity Target: Recent In Silico Advances in the Comprehension of the Protein-Protein Interaction and Rational Drug Design of Anti- Obesity Lead Compounds
Current Pharmaceutical Design The Novel Multi-Target Iron Chelator, M30 Modulates HIF-1α-Related Glycolytic Genes and Insulin Signaling Pathway in the Frontal Cortex of APP/PS1 Alzheimer’s Disease Mice
Current Alzheimer Research Extraction, Characterization and In Vivo Neuromodulatory Activity of Phytosterols from Microalga Dunaliella Tertiolecta
Current Medicinal Chemistry CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) Synaptic Plasticity in PTSD and associated Comorbidities: The Function and Mechanism for Diagnostics and Therapy
Current Pharmaceutical Design Editorial [Hot Topic: Chemokine Inhibitors as Anti-Inflammatory Drugs (Executive Editor: David J. Grainger)]
Mini-Reviews in Medicinal Chemistry Physiological Changes in the Critically Ill Patient with Sepsis
Current Pharmaceutical Biotechnology Role of Microglia in the Pathogenesis of Sepsis-Associated Encephalopathy
CNS & Neurological Disorders - Drug Targets Activation of Adenosine Receptor Potentiates the Anticonvulsant Effect of Phenytoin Against Amygdala Kindled Seizures
CNS & Neurological Disorders - Drug Targets Congenital Muscular Dystrophy 1D Causes Matrix Metalloproteinase Activation And Blood-Brain Barrier Impairment
Current Neurovascular Research Cancer Treatment-Induced Cardiotoxicity: a Cardiac Stem Cell Disease?
Cardiovascular & Hematological Agents in Medicinal Chemistry Is There a Relationship between Impulsivity and Depression in Adults? A Research Synthesis
Current Psychiatry Reviews Update in the Management of Diastolic Heart Failure
Current Vascular Pharmacology Anti-Inflammatory and Antioxidant Properties of Piper Species: A Perspective from Screening to Molecular Mechanisms
Current Topics in Medicinal Chemistry In vitro and in vivo Assessment of Silver Nanoparticles Against Clostridium botulinum Type A Botulinum
Current Drug Discovery Technologies Genetics of Cholesterol and Lipoprotein Metabolism
Recent Patents on Cardiovascular Drug Discovery Basal Ganglia Enlarged Perivascular Spaces are Linked to Cognitive Function in Patients with Cerebral Small Vessel Disease
Current Neurovascular Research Cardiac Regeneration by Progenitor Cells: What Is It Known as and What Is It Still to Be Known as?
Cardiovascular & Hematological Agents in Medicinal Chemistry The Renin-Angiotensin System in the Mammalian Central Nervous System
Current Protein & Peptide Science